Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.

Nature·2021
Same author

Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

Circulation·2021
Same author

Periodontal Disease, Atrial Fibrillation and Stroke.

American heart journal·2021
Same author

Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study.

Journal of clinical gastroenterology·2021
Same author

Sphingolipids and physical function in the Atherosclerosis Risk in Communities (ARIC) study.

Scientific reports·2021
Same author

Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals.

JAMA network open·2021
Same journal

Cohort profile: Sheyang Mini Birth Cohort Study (SMBCS).

BMJ open·2026
Same journal

Quebec lung, liver and heart transplant recipients' perspectives on self-narratives and their experiences in creative writing workshops during the transplantation journey: a qualitative study.

BMJ open·2026
Same journal

Impact of climatic variables on postoperative outcomes in various surgical disciplines: a systematic review.

BMJ open·2026
Same journal

ADHD and cardiometabolic risk profile in adults with type 2 diabetes: a longitudinal register-based study.

BMJ open·2026
Same journal

Understanding the impact of the follow-up period on the association between excess body weight, and cardiovascular events and mortality: a prospective cohort study of the UK Biobank.

BMJ open·2026
Same journal

Temporal associations between incident physical health problems/sensory impairments and challenging behaviours in people with intellectual disabilities: a population-based longitudinal cohort study of primary care in England.

BMJ open·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study.

Juan Erviti1, Alvaro Alonso, Javier Gorricho

  • 1Drug Prescribing Service, Navarre Regional Health Service, Pamplona, Navarre, Spain.

BMJ Open
|February 23, 2013
PubMed
Summary
This summary is machine-generated.

Long-term bisphosphonate use in older women did not decrease hip fracture risk. However, use exceeding three years showed a statistically significant increased risk of hip fracture.

Related Experiment Videos

Last Updated: May 14, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
07:20

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

Area of Science:

  • Gerontology
  • Pharmacovigilance
  • Bone Health

Background:

  • Bisphosphonates are commonly prescribed to prevent fractures in older adults.
  • The long-term effects of bisphosphonates on hip fracture risk require ongoing investigation.

Purpose of the Study:

  • To assess the association between long-term bisphosphonate use and hip fracture risk in women aged 65 and older.
  • To compare hip fracture risk in bisphosphonate users versus non-users.

Main Methods:

  • A nested case-control study was conducted using a Spanish general practice research database.
  • 2009 hip fracture cases were matched with 10,045 controls aged 65+.
  • Data on bisphosphonate use, comorbidities, and comedications were collected.

Main Results:

  • Overall bisphosphonate use was not associated with a different risk of hip fracture compared to never use (OR=1.09).
  • No association was found between cumulative bisphosphonate duration and hip fracture risk.
  • A significant increase in hip fracture risk was observed with bisphosphonate exposure of 3 years or longer (OR=1.32).

Conclusions:

  • Ever use of oral bisphosphonates is not associated with a reduced risk of hip fracture in older women.
  • While cumulative duration showed no link, prolonged exposure (≥3 years) to bisphosphonates may increase hip fracture risk.